Gilead

AHF Doubles Down, Hammers Gilead’s Greed in SF Chronicle Ad

Retrieved on: 
Saturday, October 29, 2022
AIDS, Public Policy, Government, Health, Healthcare Reform, Infectious Diseases, Advocacy Group Opinion, Pharmaceutical, Gilead Sciences, KGO, CA, San Francisco Chronicle, Multimedia, Tenofovir alafenamide, HRSA, Safety, Patent, AIDS Healthcare Foundation, Gilead, AIDS, Sunday Chronicle, AHF, HIV, Hospital, Patient, HIV/AIDS, KPIX, Hepatitis, Pharmaceutical industry, San Francisco Bay Area

The ad, which will run in the San Francisco Chronicle, is simply headlined Greed, however, the word greed is scratched out with three red letters superimposed over Gileads logo to create the word.

Key Points: 
  • The ad, which will run in the San Francisco Chronicle, is simply headlined Greed, however, the word greed is scratched out with three red letters superimposed over Gileads logo to create the word.
  • The ad, which will run in the San Francisco Chronicle, is simply headlined Greed, however, the word greed is scratched out with three red letters superimposed over Gileads logo to create the word.
  • The ad also includes an image of company CEO Daniel ODay under a microscope on a field of U.S. currency.
  • The Sunday Chronicle ad comes on the heels of a successful grassroots advocacy campaign ending today (10/28).

EQS-News: This Company Is Looking For A Monkeypox Drug As City Investigates Deaths

Retrieved on: 
Friday, October 28, 2022
Eye, IND, Dengue fever, Company, Bird, Virus, Drug development, Pox, Skin cream, Death, Rash, US, Safety, CGMP, Gilead, Disease, VZV, Food, Shingles, HCV, Hepatitis B virus, HIV, Patient, Technology, HBV, Remdesivir, Keratitis, Food and Drug Administration, Research, COVID-19, Degenerative disease, Hepatitis C, Influenza, FDA, Consultant, NYSE, Monkeypox, US FDA, Advertising, EKC, Vaccine, Pharmaceutical industry, West Nile virus, Rabies

Tackling monkeypox head-on, NanoViricides Inc. (NYSE: NNVC) is launching a monkeypox initiative.

Key Points: 
  • Tackling monkeypox head-on, NanoViricides Inc. (NYSE: NNVC) is launching a monkeypox initiative.
  • NanoViricides believes it will be able to develop a drug in response to monkeypox in relatively quick order.
  • NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy.
  • The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable.

The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program

Retrieved on: 
Tuesday, October 25, 2022
Other Education, Other Health, University, Pharmaceutical, Education, Oncology, General Health, Philanthropy, Clinical Trials, Science, Biotechnology, Other Philanthropy, Other Science, Health, Research, HC, Interest, Medicine, Science, Program, American Association, Bristol Myers Squibb, Cancer, Population, VCU, BMSF, Foundation, Knowledge, Curriculum, AACR, CDA, Clinical trial, Degenerative disease, Risk, American Association for Cancer Research, Woman, Diagnosis, Health equity, Research, Workforce, Multimedia, Gilead Sciences, Student, HIV, URM, VCU Massey Cancer Center, Physician, Caregiver, Cardiovascular disease, Disease, Implementation, Education, Patient, Man, Virginia Commonwealth University, Gilead, Awareness, Faculty, Humanities, Heart, School, Pharmaceutical industry, Oncology, MD, Doctor of Philosophy

The 64 physicians selected by an independent national review committee are from a broad range of healthcare institutions in 22 states across the U.S. These Winn Scholars -- 41 women and 23 men -- represent a diverse cross section of races and ethnicities and bring a widely varied perspective to the program, practicing in the therapeutic areas of cancer (hematologic or solid tumors), immunologic disorders and cardiovascular diseases. They join the 52 physicians awarded to the two-year program in November 2021.

Key Points: 
  • We are mindful that advancing diversity in clinical trials is a long-term initiative whose success depends on deep engagement at the community level.
  • Through the Winn Award Programs Winn CDA, physicians are being trained as world-class clinical research scientists with additional knowledge, skills and competencies in effective community outreach and engagement.
  • The Winn Award Program also offers an award to medical students who are underrepresented in medicine (URM), called the Robert A. Winn Clinical Investigator Pathway Program (Winn CIPP).
  • The Winn Award Program embodies AACRs commitment to advancing equitable cancer research for the benefit of all patients.

HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers

Retrieved on: 
Thursday, October 20, 2022
CD8, NASDAQ, Roche, Patient, Epitope, Research, Cell, KRAS, Cancer, HIV, NEW, Arenavirus, Mutation, Gilead, Immunotherapy, Prostate cancer, GLOBE, HBV, Human papillomavirus infection, Leadership, Pharmaceutical industry, Vaccine, Antibiotics

Through the collaboration, HOOKIPA will conduct research and early clinical development through Phase 1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers.

Key Points: 
  • Through the collaboration, HOOKIPA will conduct research and early clinical development through Phase 1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers.
  • The agreement also includes an option for Roche to license a second arenaviral cancer immunotherapy.
  • Roche is an ideal partner, both in terms of development and reaching patients with novel cancer therapeutics.
  • HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers.

Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer

Retrieved on: 
Thursday, October 13, 2022
Regulatory T cell, McKinsey & Company, Therapy, Growth, Infection, IND, Degenerative disease, Scleroderma, Patient, Synthetic biology, Research, Investigational New Drug, NIH, Multimedia, CAR, Regulation, Transplant, Lupus nephritis, R, Industry, National, CEO, Gilead, Health, Myopathy, CD19, Autoimmunity, Intellia Therapeutics, Inflammation, Personalized medicine, BD, Engineering, Pharmaceutical industry, Management, Vaccine, Novartis

EMERYVILLE, Calif., Oct. 13, 2022 /PRNewswire/ --  Kyverna Therapeutics ("Kyverna"), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of Peter K. Maag, Ph.D., as the company's chief executive officer (CEO). Dr. Maag succeeds Dominic Borie, M.D., Ph.D., who has been named Kyverna's president of research and development (R&D). Dr. Maag also joins Kyverna's board of directors.

Key Points: 
  • "We are thrilled to welcome Peter as Kyverna's new CEO," said Ian Clark, chair of Kyverna's board of directors.
  • Dr. Maag has more than 20 years of executive management experience in the pharmaceutical and diagnostic industry.
  • "I am passionate about patient care and am honored to be appointed to lead Kyverna and this extraordinarily talented team.
  • Kyverna Therapeutics is a cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases.

Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID

Retrieved on: 
Wednesday, October 12, 2022
Quality of life, U.S. Department of Defense Strategy for Operating in Cyberspace, Pancreatic cancer, PDAC, United States Department of Health and Human Services, Biomedical Advanced Research and Development Authority, Communication, Therapy, SEC, Development, Human services, Diagnosis, EC50, Pneumonia, GMP, Severe acute respiratory syndrome coronavirus 2, COVID, DIPG, Patient, Brain, Research, Annual report, JV, Cancer, Private Securities Litigation Reform Act, BARDA, Form 10-K, Administration, Company, Department, Gilead, Adult, Optimism, Ageing, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Radiation, Fibrosis, GLOBE, Forward-looking statement, Breathe Me, COVID-19, OTCQB, Risk, Pharmaceutical industry, Dragon

The data will be used to design the next clinical trial aiming at demonstrating effectiveness of OT-101 against COVID-19 and long-term COVID-19.

Key Points: 
  • The data will be used to design the next clinical trial aiming at demonstrating effectiveness of OT-101 against COVID-19 and long-term COVID-19.
  • OT-101 has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer.
  • It has pediatric designation for a rare form of pediatric brain cancer known as DIPG.
  • Forward-looking statements are based on expectations and assumptions as of the date of this press release.

ISPE Announces Leaders from FDA, Pfizer, Takeda, Cognizant, and Gilead to Speak at Annual Meeting & Expo

Retrieved on: 
Monday, October 10, 2022
Adult, Program, Ness Digital Engineering, OTC, American College, PGS, Solution, Plasma, Center for Biologics Evaluation and Research, Policy, Global, Internal medicine, Senior, International Society, Global supply chain management, Physician, Digital, FDA, Time, Organization, Gilead Sciences, Medication, Association, Pharmacist, Hematology, ISPE, Name, Cognizant, Compliance, Risk management, Yale University, HBU, CBER, NORTH, Acquisition, Doctor of Philosophy, MD, Information technology, Gilead, OPQ, Oncology, Center, COVID-19, Pharmaceutical industry, Video game, Management, Fine chemical, Pfizer, Takeda, Research

NORTH BETHESDA, Md., Oct. 10, 2022 /PRNewswire-PRWeb/ -- The International Society for Pharmaceutical Engineering (ISPE) announced seven keynote speakers for the 2022 ISPE Annual Meeting & Expo, taking place 30 October–2 November 2022 in Orlando, Florida, and virtually. This signature event brings together top pharmaceutical industry and regulatory leaders offering compelling presentations and interactive discussions on industry-critical technical developments.

Key Points: 
  • The International Society for Pharmaceutical Engineering (ISPE) announced seven keynote speakers for the 2022 ISPE Annual Meeting & Expo, taking place 30 October2 November 2022 in Orlando, Florida, and virtually.
  • This signature event brings together top pharmaceutical industry and regulatory leaders offering compelling presentations and interactive discussions on industry-critical technical developments.
  • NORTH BETHESDA, Md., Oct. 10, 2022 /PRNewswire-PRWeb/ -- The International Society for Pharmaceutical Engineering (ISPE) announced seven keynote speakers for the 2022 ISPE Annual Meeting & Expo , taking place 30 October2 November 2022 in Orlando, Florida, and virtually.
  • The 2022 ISPE Annual Meeting & Expo features a dynamic line-up of thought-provoking keynote presentations led by some of the most prominent names in the pharmaceutical industry.

Schrödinger Hosts Platform Day

Retrieved on: 
Thursday, October 6, 2022
Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, Method, LinkedIn, Psoriasis, U.S. Securities and Exchange Commission, MBBS, Therapy, CDC7, Efficiency, Review, Lilly, Machine learning, Growth, Private Securities Litigation Reform Act, Patient, Drug development, ACC, Twitter, Research, Instagram, Program, Eli Lilly and Company, Fatty liver disease, Security (finance), Nasdaq, Technology, NASH, Knowledge, Wee1, Trial of the century, Company, Marketing, Gilead, ADME, Baozou Big News Events, Blog, Ulcerative colitis, TYK2, Cirrhosis, COVID-19, Risk, Pharmaceutical industry, Fine chemical, IND, MALT1

Schrdinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, is providing a detailed review of its technology platform, the impact of this platform across a growing portfolio of collaborative and proprietary drug discovery programs, areas for future innovation, and the opportunities for value creation during its Platform Day today, October 6, from 10:00 a.m. - 12:00 p.m.

Key Points: 
  • Schrdinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, is providing a detailed review of its technology platform, the impact of this platform across a growing portfolio of collaborative and proprietary drug discovery programs, areas for future innovation, and the opportunities for value creation during its Platform Day today, October 6, from 10:00 a.m. - 12:00 p.m.
  • Under the terms of the agreement, Schrdinger will be responsible for the discovery and optimization of small molecule compounds addressing the target.
  • In todays presentation, six case studies are being highlighted that demonstrate how Schrdinger leverages the platform to overcome molecular design challenges.
  • Schrdinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods.

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor

Retrieved on: 
Wednesday, October 5, 2022
Slate, SAN, Education, International League, Therapy, HDV, Science, Securities Act of 1933, Assembly, Hepatitis B virus, CEO, State Bar of California, University of California, Hastings College of the Law, LLP, HSV, Technology, Human Resources, Science, and Technology Committee, U.S. Securities and Exchange Commission, Skadden, Gilead Sciences, Knowledge, Industry, GLOBE, Â, Sumathi Best Television Current Reporting Award, Leadership, Parliamentary Information Technology Committee, Annual report, Degenerative disease, Board, Securities Exchange Act of 1934, HBV, Minnesota State Bar Association, SEC, COO, Patient, Partnership, MD, Doctor of Philosophy, Health, Information technology, UC, Gilead, Safety, Stanford University, AO, COVID-19, Lead, Management, Pharmaceutical industry

Dr. McHutchison will continue to serve on Assembly Bios Board of Directors, including assuming the role of chairman of the Science and Technology Committee.

Key Points: 
  • Dr. McHutchison will continue to serve on Assembly Bios Board of Directors, including assuming the role of chairman of the Science and Technology Committee.
  • Assembly Bios Board of Directors has unanimously elected Jason A. Okazaki, the companys current president and chief operating officer (COO), as chief executive officer and a member of the board upon Dr. McHutchisons retirement.
  • In partnership with our management team and me, he has enabled Assembly Bio to expand beyond core inhibition into complementary HBV-cure mechanisms and other novel viral targets.
  • The Board and I are grateful for the tremendous progress Assembly Bio has made under Johns leadership, said William R. Ringo, Jr., chairman of the Assembly Bio Board of Directors.

Hepatitis Drugs Global Market Report 2022: Featuring Gilead, F Hoffmann-La Roche, Johnson & Johnson, Merck & GlaxoSmithKline PLC - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
Health, Pharmaceutical, Hepatitis, Hepatocyte, Gilead Sciences, World Health Organization, Liver, WHO, Discovery and development of NS5A inhibitors, Asia-Pacific, Growth, HIV, Infection, NTCP, MYR, Acquisition, Interferon-alpha/beta receptor, Gilead, Route of administration, Injection, Thrombopoiesis, Nasal administration, Vaccine, Pharmaceutical industry

The "Hepatitis Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepatitis Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The increasing number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drugs market.
  • Various types of hepatitis need different drugs for treatment and this increases the demand for hepatitis drugs.